← All trials
NCT05922124
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Jul 31, 2025
- Completion date
- Sep 30, 2025
- First posted
- Jun 28, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 734
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Technion UniversityLead sponsor
- Hebrew UniversityCollaborator
- Monaldi HospitalCollaborator
- Technion UniversityOverall official - principal investigator
- Rutgers UniversityCollaborator
- Tel Aviv UniversityCollaborator
- Tel Aviv UniversityOverall official - principal investigator
- Tel Aviv UniversityOfficial
- Technion UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.